RT Journal Article
SR Electronic
T1 Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-COV-2 infection: a retrospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.05.20123299
DO 10.1101/2020.06.05.20123299
A1 Andrea Giacomelli
A1 Gabriele Pagani
A1 Anna Lisa Ridolfo
A1 Letizia Oreni
A1 Federico Conti
A1 Laura Pezzati
A1 Lucia Bradanini
A1 Giacomo Casalini
A1 Cinzia Bassoli
A1 Valentina Morena
A1 Simone Passerini
A1 Giuliano Rizzardini
A1 Chiara Cogliati
A1 Elisa Ceriani
A1 Riccardo Colombo
A1 Stefano Rusconi
A1 Cristina Gervasoni
A1 Dario Cattaneo
A1 Spinello Antinori
A1 Massimo Galli
YR 2020
UL http://medrxiv.org/content/early/2020/06/12/2020.06.05.20123299.abstract
AB As it has been shown that lopinavir (LPV) and hydroxychloroquine (HCQ) have in vitro activity against coronaviruses, they were used to treat COVID-19 during the first wave of the epidemic in Lombardy, Italy.The aim of this retrospective intent-to-treat analysis of the hospitalized patients who started off-label treatment with LPV/ritonavir (LPV/r)+HCQ between 21 February and 20 March 2020 was to compare the rate of clinical improvement between those who started the treatment within five days of symptom onset (early treatment, ET) and those who started later (delayed treatment, DT). The association between the timing of treatment and the probability of 30-day mortality was also assessed using uni- and multivariable logistic models.The study involved 172 patients: 43 (25%) in the ET and 129 (75%) in the DT group. The rate of clinical improvement increased over time to 73.3% on day 30, without any significant difference between the two groups (Gray’s test P = 0.213). After adjusting for potentially relevant clinical variables, there was no significant association between the timing of the start of treatment and the probability of 30-day mortality (adjusted odds ratio [aOR] ET vs DT = 1.45, 95% confidence interval 0.50-4.19). Eight percent of the patients discontinued the treatment because of severe gastrointestinal disorders attributable to LPV/r.The timing of the start of LPV/r+HCQ treatment does not seem to affect the clinical course of hospitalised patients with COVID-19. Together with the severe adverse events attributable to LPV/r, this raises concerns about the benefit of using this combination to treat COVID-19.Competing Interest StatementAG received consultancy fees from Mylan and non-financial educational support from Gilead. SR received grants, fees for speaker's bureau, advisory boards and CME activities from BMS, ViiV, MSD, AbbVie, Gilead, Janssen. MG received grants, fees for speaker's bureau, advisory boards and CME activities from BMS, ViiV, MSD, AbbVie, Gilead, Janssen and Roche. GR received grants, fees for speaker's bureau, advisory boards and CME activities from BMS, ViiV, MSD, AbbVie, Gilead, Janssen and Roche. SA received support for research activities from Pfizer and Merck Sharp & Dome. GP, LO, CB, FC, LP, LB, SP, AT, GC, VM, PS, CC, EC, AMB, RC, MC, GG have nothing to declare.Funding StatementThe study was not funded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by our Comitato Etico Interaziendale Area 1. Al patients signed a written informed consent for the off-label treatment with lopinavir/ritonavir and hydroxychloroquine. Informed consent was waived in the case of patients undergoing mechanical ventilation upon admission.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.Abbreviations:CCICharlson Comorbidity IndexETearly treatment groupDTdelayed treatment grouppaO2partial oxygen pressureD-dD-dimerNAnot assignedCRPC-reactive proteinaORadjusted odds ratioLoglogarithmic.COVID-19coronavirus induced diseaseSARS-CoV-2severe acute respiratory syndrome coronavirus 2ETearly treatmentDTdelayed treatmentHCoV-229EHuman coronavirus 229ETNF-1Tumor necrosis factor 1IL-6interleukin 6MERSMiddle Eastern Respiratory Syndrome CoronavirusLPV/rlopinavir/ritonavirHCQhydroxychloroquineSIMITSocietà Italina di Malattie Infettive e TropicaliRT-PCRreal time polymerase chain reactionSpO2percutaneous oxygen saturationCCICharlson comorbidity indexFiO2fraction of inspired oxygenPaO2arterial partial pressure of oxygenIQRinter quartile rangeICUintensive care unitECMOExtra corporeal membrane oxygenationCRPC-reactive proteinOROdds RatioaORadjusted Odds RatioCIConfidence IntervalAEAdverse EventsPA-IC90protein-adjusted 90% inhibitory concentrationELFepithelial lining fluidCSFcerebrospinal fluid